<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02880644</url>
  </required_header>
  <id_info>
    <org_study_id>HERMES</org_study_id>
    <nct_id>NCT02880644</nct_id>
  </id_info>
  <brief_title>Ultra-wide Fluorescein Angiography in Patients With Central Retinal Vein Occlusion Treated by Afilbercept</brief_title>
  <acronym>HERMES</acronym>
  <official_title>Ultra-wide Fluorescein angiograpHy to Evaluate the Progression of Retinal ischeMia After aflibErcept Injections in patientS With Central Retinal Vein Occlusion in Real Life (HERMES Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal Creteil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with macular edema secondary to CRVO, Aflibercept demonstrated efficacy and
      safety in 2 parallel trials, interventional phase III studies, COPERNICUS study performed in
      United States and GALILEO study performed in Europe and Asia/Pacific.

      With the project of Hermes Study, the first observational study conducted in France in
      patients with CRVO and treated with aflibercept, we would like to evaluate in real life the
      monitoring and the use of Aflibercept. The primary objective of this study will also be based
      on anatomic outcomes. The evolution of retinal ischemia and the degree of non-retinal
      perfusion will be particularly evaluated by using ultra wide field angiography technology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pathophysiology of Central Retinal Vein Occlusion (CRVO) is incompletely understood, but
      a significant slow-down in blood flow, caused by various predisposing factors, results in the
      release of VEGF, leading to the breakdown of the blood-retinal-barrier and finally to macular
      edema. The level of VEGF has been also correlated with neovascularization and vascular
      permeability in patients with ischemic CRVO. Several treatments have been used to treat
      patients with CRVO such as hemodilution, surgery, laser treatment and corticoids injection.
      However anti-vascular endothelial growth factor (anti-VEGF) agents administered by
      intravitreal injection, improve both visual and anatomic outcomes in patients with macular
      edema secondary to CRVO. Aflibercept is a fusion protein, use by intravitreal injection. In
      patients with macular edema secondary to CRVO, Aflibercept demonstrated efficacy and safety
      in 2 parallel trials, interventional phase III studies, COPERNICUS study performed in United
      States and GALILEO study performed in Europe and Asia/Pacific. In these studies, anatomic
      outcomes such as ischemic progression and retinal perfusion status were evaluated as
      secondary objectives; the primary objective of these studies was visual outcome.

      With the project of Hermes Study, the first observational study conducted in France in
      patients with CRVO and treated with aflibercept, we would like to evaluate in real life the
      monitoring and the use of Aflibercept. The primary objective of this study will also be based
      on anatomic outcomes. The evolution of retinal ischemia and the degree of non-retinal
      perfusion will be particularly evaluated by using ultra wide field angiography technology.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Change from baseline in non-perfused areas in both macula and peripheral retina at 12 months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in visual acuity from baseline to months 3, 6, 12 and 24</measure>
    <time_frame>Baseline and 3, 6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in non-perfused areas in both macula and peripheral retina at 3, 6 and 12 months</measure>
    <time_frame>Baseline and 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time between the last two injections</measure>
    <time_frame>Up to 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of injections by patient from baseline to end-of-study visit</measure>
    <time_frame>From baseline to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of visits by patient from baseline to end-of-study visit</measure>
    <time_frame>From baseline to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in central retinal thickness at 3, 6, 12 and 24 months</measure>
    <time_frame>Baseline and 3, 6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vascular density in OCT-A from baseline to months 3, 6, 12, 24</measure>
    <time_frame>Baseline and 3, 6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Retinal Vein Occlusion</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with central retinal vein occlusion
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman aged 18 years or more

          -  Patients with a diagnosis of CRVO (presence of retinal hemorrhages associated with
             vein dilation and tortuosity in the 4 quadrants)

          -  The decision for treatment with Aflibercept (Eylea®) has been made for patients with a
             decrease in Best Corrected Visual Acuity (BCVA) and macular edema

          -  Duration of CRVO not more than 4 months

          -  Naïve patients. Patient with previous CRVO (more than 12 months before the inclusion
             date) which completely resolved (normalization of visual acuity and fundus
             examination) and who experienced a recurrence of CRVO are also considered naive

          -  Patient who agrees to participate to the study and who has given his/her written,
             informed consent

        Exclusion Criteria:

          -  Patient with another retinal disease in the study eye: diabetic retinopathy,
             maculopathy of any cause (age-related macular degeneration, epimacular membrane,
             myopia, etc) responsible for decreased vision, advanced glaucoma, cataract severely
             affecting vision and/or requiring surgical treatment during the 24 months study period

          -  Patient who does not meet the local indication criteria for aflibercept treatment.
             Contraindications listed in the SmPCs must be taken into account including:

          -  Hypersensitivity to the active substance aflibercept or to any of the excipients
             listed in SmPC of the product

          -  Active or suspected ocular or periocular infection

          -  Active severe intraocular inflammation

          -  CRVO complicated with neovascularization of the anterior segment

          -  Patient who has previously undergone laser panretinal photocoagulation, grid-laser or
             photodynamic therapy, any anti-VEGF or corticoids intravitreal injections in the study
             eye

          -  Patient already included in the study for the treatment of the fellow eye

          -  Pregnant or breastfeeding woman

          -  Lack of effective contraception for women of childbearing age

          -  Patient taking part in an interventional study

          -  Patients not covered by the French Health Insurance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agnès GLACET-BERNARD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Intercommunal Créteil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Agnès GLACET-BERNARD, MD</last_name>
    <phone>+331 45 17 52 21</phone>
    <email>agnes.glacet@chicreteil.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amelle ISSA</last_name>
    <phone>+331 57 02 26 32</phone>
    <email>amelle.issa@chicreteil.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal Créteil</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnès Glacet-Bernard, MD</last_name>
      <email>agnes.glacet@chicreteil.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Monticelli Paradis d'Ophtalmologie</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Morel, MD</last_name>
      <email>cvmorel@orange.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire De Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel Weber, MD PhD</last_name>
      <email>michel.weber@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Michel Weber, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène Masse, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chloé Couret, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guylène Le Meur, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre Bonissent, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clémence Carbonniere, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nice-Saint-Roch</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie Baillif, MD PhD</last_name>
      <email>baillif.s@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'exploration ophtalmologique de l'odéon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Coscas, MD</last_name>
      <email>coscas.f@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'Imagerie et de laser</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia Nghiem Buffet, MD</last_name>
      <email>buffet.nghiem@free.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHNO des Quinze-Vingts</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-François Girmens, MD</last_name>
      <email>jfgirmens@quinze-vingts.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière - APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ramin Tadayoni, MD PhD</last_name>
      <email>ramin.tadayoni@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Ali Erginay, MD</last_name>
      <email>ali.erginay@aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Ali Erginay, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré - CHU Reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl Arndt, MD PhD</last_name>
      <email>carl.arndt@orange.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Williamson TH. Central retinal vein occlusion: what's the story? Br J Ophthalmol. 1997 Aug;81(8):698-704. Review.</citation>
    <PMID>9349161</PMID>
  </reference>
  <reference>
    <citation>Hayreh SS. So-called &quot;central retinal vein occlusion&quot;. I. Pathogenesis, terminology, clinical features. Ophthalmologica. 1976;172(1):1-13.</citation>
    <PMID>1250571</PMID>
  </reference>
  <reference>
    <citation>Fujikawa M, Sawada O, Miyake T, Kakinoki M, Sawada T, Kawamura H, Ohji M. Correlation between vascular endothelial growth factor and nonperfused areas in macular edema secondary to branch retinal vein occlusion. Clin Ophthalmol. 2013;7:1497-501. doi: 10.2147/OPTH.S46817. Epub 2013 Jul 19.</citation>
    <PMID>23901258</PMID>
  </reference>
  <reference>
    <citation>Noma H, Minamoto A, Funatsu H, Tsukamoto H, Nakano K, Yamashita H, Mishima HK. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2006 Mar;244(3):309-15. Epub 2005 Aug 13.</citation>
    <PMID>16133018</PMID>
  </reference>
  <reference>
    <citation>Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Arch Ophthalmol. 1997 Apr;115(4):486-91. Erratum in: Arch Ophthalmol 1997 Oct;115(10):1275.</citation>
    <PMID>9109757</PMID>
  </reference>
  <reference>
    <citation>Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology. 1995 Oct;102(10):1425-33.</citation>
    <PMID>9097788</PMID>
  </reference>
  <reference>
    <citation>Opremcak EM, Rehmar AJ, Ridenour CD, Kurz DE. Radial optic neurotomy for central retinal vein occlusion: 117 consecutive cases. Retina. 2006 Mar;26(3):297-305.</citation>
    <PMID>16508430</PMID>
  </reference>
  <reference>
    <citation>Glacet-Bernard A, Atassi M, Fardeau C, Romanet JP, Tonini M, Conrath J, Denis P, Mauget-Faÿsse M, Coscas G, Soubrane G, Souied E. Hemodilution therapy using automated erythrocytapheresis in central retinal vein occlusion: results of a multicenter randomized controlled study. Graefes Arch Clin Exp Ophthalmol. 2011 Apr;249(4):505-12. doi: 10.1007/s00417-010-1532-5. Epub 2010 Oct 17.</citation>
    <PMID>20953877</PMID>
  </reference>
  <reference>
    <citation>Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009 Sep;127(9):1101-14. doi: 10.1001/archophthalmol.2009.234. Erratum in: Arch Ophthalmol. 2009 Dec;127(12):1648.</citation>
    <PMID>19752419</PMID>
  </reference>
  <reference>
    <citation>Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010 Jun;117(6):1134-1146.e3. doi: 10.1016/j.ophtha.2010.03.032. Epub 2010 Apr 24.</citation>
    <PMID>20417567</PMID>
  </reference>
  <reference>
    <citation>Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011 Oct;118(10):2041-9. doi: 10.1016/j.ophtha.2011.02.038. Epub 2011 Jun 29.</citation>
    <PMID>21715011</PMID>
  </reference>
  <reference>
    <citation>Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sandbrink R, Haller JA. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014 Jul;121(7):1414-1420.e1. doi: 10.1016/j.ophtha.2014.01.027. Epub 2014 Mar 27. Erratum in: Ophthalmology. 2014 Nov;121(11):2293.</citation>
    <PMID>24679444</PMID>
  </reference>
  <reference>
    <citation>Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R; GALILEO Study Group. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol. 2014 Nov;158(5):1032-8. doi: 10.1016/j.ajo.2014.07.027. Epub 2014 Jul 25.</citation>
    <PMID>25068637</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2016</study_first_submitted>
  <study_first_submitted_qc>August 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2016</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Intercommunal Creteil</investigator_affiliation>
    <investigator_full_name>Agnes Glacet-Bernard</investigator_full_name>
    <investigator_title>Ophtalmologist</investigator_title>
  </responsible_party>
  <keyword>Central retinal vein occlusion</keyword>
  <keyword>OCT-A</keyword>
  <keyword>CRVO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

